

***Fiscal Year 2024 Department of Defense Prostate Cancer Research Program (PCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Data Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PCRPDSA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> • Supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. • Applications may propose development of a new data science-driven tool or apply an existing tool or method to gather and analyze information from large data sets with the intent of advancing prostate cancer research and patient care relative to the FY24 PCRP Overarching Challenges. • Research efforts must be built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer: <ul style="list-style-type: none"> ○ Analysis of clinically annotated datasets ○ Analysis of -omics data ○ Artificial intelligence and machine learning ○ Bioinformatics ○ Computational biology ○ Digital pathology ○ Epidemiology ○ Medical imaging • <i>Clinical research is allowed but must be retrospective; prospective recruitment of human subjects and/or clinical trials are not allowed.</i> • Presentation of preliminary data is strongly encouraged, but not required. • Each investigator may be named as Principal Investigator (PI) on only one application. • <i>Partnering PI Option:</i> Allows two PIs, termed the Initiating and Partnering PIs, to collaborate on a single application. Collaborations between data scientists and clinicians are highly encouraged. At least one of the submitting or partnering PIs must have expertise in prostate cancer basic and/or clinical research. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,000,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): August 9, 2024 5:00 p.m. Eastern time</p> <p>Application: August 30, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Early Investigator Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PCRPEIRA</p>	<p><i>By March 31, 2025,</i></p> <p>Post-doctoral PIs:</p> <ul style="list-style-type: none"> Must possess a doctoral degree (or equivalent) Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) 	<ul style="list-style-type: none"> Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers. PIs must have a designated mentor who is an experienced prostate cancer researcher. Applications must include a Researcher Development Plan articulating an individualized strategy for acquiring the necessary skills, competence, and expertise to complete the project and foster the PI’s career development. <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$300,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): August 9, 2024 5:00 p.m. Eastern time</p> <p>Application: August 30, 2024 11:59 p.m. Eastern time</p> <p>Confidential Letters of Recommendation: September 4, 2024 5:00 p.m. Eastern time</p>
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PCRPEHDA</p>	<p>Investigators at or above the level of post-doctoral fellow (or equivalent)</p>	<ul style="list-style-type: none"> Supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer. Emphasis is on innovation; the potential impact may be difficult to predict. Presentation of preliminary data is strongly discouraged. <i>Clinical research is allowed.</i> <i>Clinical trials are not allowed.</i> Reviewers will be blinded to the identity of the PI, collaborators, and their organization(s). 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$150,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): June 21, 2024 5:00 p.m. Eastern time</p> <p>Application: July 12, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PCRPIDA</p>	<p><i>Established Investigators:</i> Independent investigators at all levels</p> <p><i>New Investigators:</i> Investigators that meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have the freedom to pursue individual aims without formal mentorship • Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award • Have either completed at least 3 years of post-doctoral training or a fellowship or are within 10 years after completion of terminal degree (excluding residency or family medical leave) 	<ul style="list-style-type: none"> • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY24 PCRP Overarching Challenges. • Emphasis is equally placed on Innovation and Impact. • Preliminary data are encouraged, but not required. • <i>Clinical trials are not allowed.</i> • Each investigator may be named as PI on only one application. • Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,200,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): June 28, 2024 5:00 p.m. Eastern time</p> <p>Application: July 19, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Implementation Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PCRPISA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> Supports studies designed to accelerate the uptake of evidence-based practice and research into regular use in prostate cancer clinical settings (e.g., health care products, technologies, practice guidelines, access to high-quality health care, models of care, etc.) to ultimately provide a solution to one or more of the FY24 PCRP Overarching Challenges. Must include preliminary and/or published data collected by the research team that support the rationale for the proposed study. Applications are strongly encouraged to address health equity and/or disproportionately affected prostate cancer patient populations. <i>Clinical trials are allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$2,000,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): August 9, 2024 5:00 p.m. Eastern time</p> <p>Application: August 30, 2024 11:59 p.m. Eastern time</p>
<p>Physician Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524PCRPPRA</p>	<p>At the time of application submission, the PI must be either:</p> <ul style="list-style-type: none"> In the last year of an accredited medical residency or medical fellowship program <p><i>Or</i></p> <ul style="list-style-type: none"> Within 5 years of having initiated a faculty appointment (including Instructor positions) 	<ul style="list-style-type: none"> Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice. PIs must have a designated mentor with an established research program in prostate cancer. Applications are strongly encouraged to demonstrate protection of at least 20% of the PI’s time for prostate cancer research (not required to be exclusive to this award). Applications must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development. <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): August 9, 2024 5:00 p.m. Eastern time</p> <p>Application: August 30, 2024 11:59 p.m. Eastern time</p> <p>Confidential Letters of Recommendation: September 4, 2024 5:00 p.m. Eastern time</p>